Table 3.
Treatment effect by EF categories
| Outcome | Event rates PBO | Event rates EPL | HR (95%CI) | Interactionp |
|---|---|---|---|---|
| Primary outcome | ||||
| EF < 40% | 20.8 (19.3‐22.4) | 17.6 (16.2‐19.0) | 0.85 (0.77‐0.95) | 0.21 |
| EF = 40% | 12.7 (9.8‐16.4) | 8.3 (6.1‐11.1) | 0.66 (0.44‐0.98) | |
| CV death | ||||
| EF < 40% | 11.9 (10.9‐13.1) | 10.0 (9.0‐11.0) | 0.84 (0.73‐0.96) | 0.39 |
| EF = 40% | 6.2 (4.3‐8.8) | 4.0 (2.7‐6.1) | 0.66 (0.38‐1.13) | |
| All‐cause death | ||||
| EF < 40% | 13.6 (12.5‐14.9) | 11.6 (10.6‐12.7) | 0.85 (0.75‐0.97) | 0.60 |
| EF = 40% | 7.6 (5.5‐10.5) | 5.7 (4.0‐8.1) | 0.75 (0.46‐1.21) | |
| HF hospitalization | ||||
| EF < 40% | 12.1 (11.0‐13.3) | 10.4 (9.4‐11.5) | 0.87 (0.75‐1.00) | 0.23 |
| EF = 40% | 8.2 (6.0‐11.4) | 5.2 (3–6‐7.6) | 0.63 (0.39‐1.04) | |
Note: The primary outcome is a composite of cardiovascular death or cardiovascular hospitalization. Median follow‐up time to death or censor = 1.3 (1.0‐1.7) years. Event rates per 100 person‐years.
Abbreviations: CV, cardiovascular; EPL, eplerenone; HF, heart failure; LVEF, left ventricular ejection fraction; PBO, placebo.